Latest News for: hdac6

Edit

Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 ...

The Paris News 18 Dec 2023
AVS100 is a novel, orally bioavailable selective HDAC6i targeting locally advanced or metastatic solid tumors, including in combination with pembrolizumab.Avstera intends to initiate the Phase Ia/b clinical trial in the first half of 2024 ....
Edit

Avstera Therapeutics Announces FDA Clearance of IND Application for AVS100, a Novel Highly Selective HDAC6 Inhibitor Targeting Solid Tumors

PR Newswire 18 Dec 2023
FDA clearance of its Investigational New Drug application (IND) for AVS100, a novel highly selective oral HDAC6 inhibitor intended to treat locally advanced or metastatic solid tumors in a Phase I clinical study. .
Edit

Tenaya Therapeutics Presents Encouraging New Clinical And Preclinical Data From HDAC6 Inhibitor Program TN-301 For ...

MENA FN 09 Oct 2023
(MENAFN - GlobeNewsWire - Nasdaq) TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants ... .
Edit

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor ...

The Eagle-Tribune 09 Oct 2023
TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants. Combination of Tenaya’s HDAC6 ...
Edit

HDAC6 score: to treat or not to treat?

TheNewsHOOK 31 Dec 2022
HDAC6 score. to treat or not to treat? ....
Edit

Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics

PR Newswire 31 Dec 2022
The manuscript, titled "Radiation therapy-induced immune response enhanced by selective HDAC6 Inhibition," was reported by first author Dr ... Alejandro Villagra, and HDAC6 inhibitor SP-2-225 was ...
Edit

Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction (Tenaya Therapeutics Inc)

Public Technologies 06 Sep 2022
TN-301 is Tenaya's highly selective small molecule inhibitor of histone deacetylase 6 (HDAC6), initially being developed for the potential treatment of heart failure with preserved ejection fraction (HFpEF).
  • 1

Most Viewed

×